300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Morocco
Seychelles
Paraguay
Botswana
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Ireland
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Kinnevik, VC Fund

Kinnevik

VC Fund

Stockholm, Sweden

Kinnevik is an industry-focused investment company with an entrepreneurial spirit. Its purpose is to build digital consumer businesses that provide more and better choices. The company does this by working in partnership with talented founders and management teams to create, invest in, and lead fast-growing businesses in developed and emergingmarkets.Kinnevik believes in delivering both shareholder and social value by building well-governed companies that contribute positively to society. Kinnevik was founded in 1936 by the Stenbeck, Klingspor, and von Horn families. Kinnevik's shares are listed on Nasdaq Stockholm's list for large-cap companies under the ticker codes KINV A and KINV B.

Total investments:
182
Last investment:
Lead investor:
43%

Last updated:

Industries Kinnevik invests in

E-CommerceHealth CareFinancial ServicesFinTechInternet

Stages Kinnevik invests in

Series BSeries CSeries ASeries DVenture - Series Unknown

Countries Kinnevik invests in

United StatesSwedenGermanyUnited KingdomDenmark

Round sizes

Series A $2M–$91MSeries B $23M–$120MSeries C $41M–$200M

Contacts

NameEmailPhoneSocials
See all 16 contacts →

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$2M–$91M
Series B
$23M–$120M
Series C
$41M–$200M

Investment Focus

Industry

  • E-Commerce 25 (14%)
  • Health Care 13 (7%)
  • Financial Services 12 (7%)
  • FinTech 10 (5%)
  • Internet 10 (5%)
See all 144 industries →

Stage

  • Series B 28 (15%)
  • Series C 21 (12%)
  • Series A 20 (11%)
  • Series D 15 (8%)
  • Venture - Series Unknown 12 (7%)
See all 17 stages →

Country

  • United States 22 (12%)
  • Sweden 12 (7%)
  • Germany 12 (7%)
  • United Kingdom 9 (5%)
  • Denmark 5 (3%)
See all 18 countries →

Team

NameTitleInvestmentsLinksEmail
Andreas Bernstrom
Andreas Bernstrom Senior Investment Director
Senior Investment Director Total investments: 13
Find email
Magnus Jakobson
Magnus Jakobson Corporate Finance Director
Corporate Finance Director Total investments: 2
Find email
Ola Nordbye
Ola Nordbye Venture & Growth Investor
Venture & Growth Investor Total investments: 2
Find email
Anders Strandberg
Anders Strandberg Legal Professional
Legal Professional Total investments: 0
Find email
Christian Scherrer
Christian Scherrer Investment Manager
Investment Manager Total investments: 11
Find email
See all 16 team members →

Investments

CompanyDescriptionRoundLinks
Tandem Health Tandem Health
Tandem Health develops AI tools that support clinical documentation, coding, decision support, and follow-up across healthcare workflows. Its AI Medical Scribe captures conversations during patient visits and converts relevant information into structured clinical notes, referrals, summaries, and other documents for review. The platform alsoprovides suggested diagnosis and procedure codes and allows clinicians to edit documentation through voice commands. Tandem Health integrates with medical record, dental, pharmacy, and care-management systems, enabling approved notes and related documents to transfer directly into existing records. Its solutions support healthcare professionals across medical, nursing, physiotherapy, dental, mental health, social care, and veterinary settings. $100M / Series B / Sep 14, 2026
Anterior Anterior
Co:Helm builds AI assistants that utilizes ChatGPT built with healthcare operations as the core focus. Co:Helm's interopability engine allows users to seamlessly integrate with any EHR or EMR system in less than a day. Co:Helm automates Prior Authorization for Utilization Management teams using AI resulting in a massive 90% time saving. $40M / Series B / Feb 12, 2026
Mews Mews
Mews is a cloud-native hospitality platform that provides property management, guest services, payments, and operations tools in a unified system. It helps hotels, hostels, and accommodation groups automate reservations, check-in/out, rate and inventory management, housekeeping, and embedded payment processing through a single dashboard. Theplatform also supports integrations with a wide range of third-party applications and open APIs to extend functionality and adapt to specific business needs. Mews emphasizes an intuitive interface and automation to reduce manual tasks and enable staff to focus on guest interactions and operational workflows. The system includes tools for revenue management, point of sale, event management, and analytics for decision support.Mews serves over 5000 properties across more than 85 countries in all five continents, and works with a huge number of hospitality tech companies to provide hoteliers with an unbeatable platform – no other PMS offers as many integrations. At the 2024 HotelTechAwards, Mews was voted Best PMS by industry peers. $300M / Series D / Jan 22, 2026
Oviva Oviva
Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). $233.7M / Series D / Jan 22, 2026
Oviva Oviva
Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). Secondary Market / Jan 22, 2026
Encube Technologies Encube Technologies
Encube Technologies operates as a visual collaboration platform where hardware teams come together to explore designs, share insights and shape ideas. $23M / Series A / Oct 16, 2025
Nory Nory
Nory is the all-knowing restaurant management system that learns the behind the scenes of your business. Helping you forecast sales, plan labour & optimise your inventory. $36.7M / Series B / Sep 15, 2025
Enveda Biosciences Enveda Biosciences
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. $150M / Series D / Sep 04, 2025
Aira Aira
Aira operates as a clean energy-tech company. $174.3M / Venture - Series Unknown / Aug 11, 2025
Strand Therapeutics Strand Therapeutics
Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer. $153M / Series B / Aug 03, 2025
See all 182 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Morocco
Seychelles
Paraguay
Botswana
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Ireland
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Kinnevik invest in?

Kinnevik invests primarily in E-Commerce, Health Care and Financial Services startups, most often at Series B and Series C stage. Most of the 182 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Kinnevik's check size?

Kinnevik typically joins rounds of $2M–$91M at Series A, $23M–$120M at Series B and $41M–$200M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kinnevik participates in.

How do I contact Kinnevik?

Public channels for Kinnevik include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Kinnevik?

The team at Kinnevik includes Andreas Bernstrom (Senior Investment Director), Magnus Jakobson (Corporate Finance Director) and Ola Nordbye (Venture & Growth Investor), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Kinnevik Kinnevik Find emails